MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer
BACKGROUND: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. METHODS: Genomic data and chromatin interaction analysis were used to discover functional promoter and enhancer elements for MIR196A. Expression data were used to associate MIR196A with mechanisms of resistance, breast cancer subtypes and prognosis. RESULTS: Here we demonstrate that MIR196A displays complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERalpha. Expression of this miRNA is significantly increased in drug-resistant models of hormone-receptor positive disease. The expression of MIR196A also proves to be a robust prognostic factor for patients with advanced and post-menopausal ER+ disease. CONCLUSION: This work sheds light on the normal and abnormal regulation of MIR196A and provides a novel stratification method for therapeutically resistant breast cancer.
|ISBN||1532-1827 (Electronic) 0007-0920 (Linking)|
|Authors||Milevskiy, M. J. G.; Gujral, U.; Del Lama Marques, C.; Stone, A.; Northwood, K.; Burke, L. J.; Gee, J. M. W.; Nephew, K.; Clark, S.; Brown, M. A.|
|Responsible Garvan Author||Prof Susan Clark|
|Publisher Name||British Journal of Cancer|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/30783203|